Viking Therapeutics (VKTX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$847.5 million.
- Viking Therapeutics' Retained Earnings fell 7371.06% to -$847.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$847.5 million, marking a year-over-year decrease of 7371.06%. This contributed to the annual value of -$847.5 million for FY2025, which is 7371.06% down from last year.
- As of Q4 2025, Viking Therapeutics' Retained Earnings stood at -$847.5 million, which was down 7371.06% from -$689.9 million recorded in Q3 2025.
- Over the past 5 years, Viking Therapeutics' Retained Earnings peaked at -$182.2 million during Q1 2021, and registered a low of -$847.5 million during Q4 2025.
- Its 5-year average for Retained Earnings is -$384.6 million, with a median of -$342.1 million in 2023.
- As far as peak fluctuations go, Viking Therapeutics' Retained Earnings tumbled by 2806.12% in 2024, and later crashed by 7371.06% in 2025.
- Viking Therapeutics' Retained Earnings (Quarter) stood at -$223.2 million in 2021, then crashed by 30.86% to -$292.0 million in 2022, then dropped by 29.41% to -$377.9 million in 2023, then fell by 29.1% to -$487.9 million in 2024, then plummeted by 73.71% to -$847.5 million in 2025.
- Its last three reported values are -$847.5 million in Q4 2025, -$689.9 million for Q3 2025, and -$599.1 million during Q2 2025.